A-796,260 is a drug developed by
Abbott Laboratories that acts as a potent and selective
cannabinoidCB2receptoragonist. Replacing the aromatic 3-
benzoyl or 3-
naphthoyl group found in most
indole derived cannabinoids with the 3-
tetramethylcyclopropylmethanone group, imparts significant selectivity for CB2, and A-796,260 was found to be a highly selective CB2 agonist with little affinity for CB1, having a CB2Ki of 4.6 nM vs 945 nM at CB1.[1] It has potent
analgesic and
anti-inflammatory actions in animal models, being especially effective in models of
neuropathic pain, but without producing cannabis-like behavioral effects.[2]
Legal Status
As of October 2015 A-796,260 is a controlled substance in China.[3]
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from
the original on 1 October 2015. Retrieved 1 October 2015.